510(k) Report

510(k) · Cleared

Cleared

BD Viper System

K052481510(k) SpecialCleared Nov 28, 200580-day reviewClass II21 CFR 866.3390

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Becton, Dickinson & CO · LSL Dna-Reagents, Neisseria

Cleared on Nov 28, 2005 as substantially equivalent to K984631 (Becton Dickinson Microbiology Systems, 1999) and 1 other predicate after an 80-day review. Its family tree reaches back 2 generations to 1994.

Decided
Nov 28, 2005
Review
80 days
Class
Class II
Product code
LSL
Recalls
None
Predicates
2

Its longest line of descent runs back 2 generations to K940390 (1994). 5 ancestors in all. No later device cites it as a predicate yet.

Other ancestors, by year cleared 1999: 1 other ancestor1997: 1 other ancestor1996: 1 other ancestorK940390 · Impact · Matrix Technologies Corp. · 1994K023955 · BD Viper Instrument · Becton, Dickinson & CO · 20031990199520002005
Other ancestors, by generation 1 generation back: 1 other ancestor2 generations back: 2 other ancestors K023955 · BD Viper Instrument · Becton, Dickinson & CO · 2003K940390 · Impact · Matrix Technologies Corp. · 19940
  1. Root · 2 generations backK940390 ImpactMatrix Technologies Corp. · 1994
  2. 1 generation backK023955 BD Viper InstrumentBecton, Dickinson & CO · 2003
  3. This deviceK052481 BD Viper SystemBecton, Dickinson & CO · 2005
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K940390ImpactMatrix Technologies Corp.1994—
−1K023955BD Viper InstrumentBecton, Dickinson & CO2003—
0 (this device)K052481BD Viper SystemBecton, Dickinson & CO2005—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199610
199710
199910
FIG. 1 — Lineage of K052481, 1994–2005Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LSL? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LSL device

  1. #1 K231329 Aptima Neisseria gonorrhoeae Assayscore 6.7 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K984631Bdprobetec ET Chlamydia Trachomatis and Neisseria Gonorrhoeae Amplified Dna Assay
Summary page 1
…ProbeTecTm ET Chiamnydia trachomatisand Neisseria gonorrhoeaeAmplified DNA Assays (K984631) BD ViperTM instrument (K023955) INTENDED USE: The BD ProbeTec ET Chiamydia trachomatis (…
Becton Dickinson Microbiology Systems19992
*K023955BD Viper Instrument
Summary page 1
…Neisseria gonorrhoeaeAmplified DNA Assays (K984631) BD ViperTM instrument (K023955) INTENDED USE: The BD ProbeTec ET Chiamydia trachomatis (CT) and Neisseria gonorrhoeae(GC) Amplified DNA Assays, when tested wi…
Becton, Dickinson & CO2003—

Also cleared against K984631: 3 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 11 years and passes through 2 companies; a new generation was cleared every 9.1 years on median.
  • 1 of the 5 ancestors has a recall of any class.
  • 3 other devices also cite its predicate K984631.

How does its category compare?

All LSL devices

LSL Dna-Reagents, Neisseria: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · LSL

1in 2024

2007: 22008: 12009: 32012: 22013: 22014: 32017: 12018: 32024: 1
2007high 3 (2009) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LSL

90in 2018

2009: 62 days median2014: 86 days median2018: 90 days median
2007high 90 (2018) · low 62 (2009)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LSL

1in 2017

2017: 1
2007high 1 (2017) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LSL

41in 2025

2009: 42010: 12011: 12013: 12014: 42015: 62016: 62017: 102018: 72019: 142020: 32021: 42022: 112023: 192024: 172025: 41
2007high 41 (2025) · low 0 (2007)2025

MAUDE reports naming product code LSL, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20081—00
200936204
20100—01
20110—01
20122—00
20132—01
201438604
20150—06
20160—06
20171—110
201839007
20190—014
20200—03
20210—04
20220—011
20230—019
20241—017
20250—041
20260—0—

What is it indicated for?

The BD ProbeTec ET Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) Amplified DNA Assays, when tested with the BD ProbeTec ET System, use Strand Displacement Amplification (SDA) technology for the direct, qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA in endocervical swabs, male urethral swabs, and in female and male urine specimens as evidence of infection with C. trachomatis, N. gonorrhoeae, or of co-infection…

Read the full statement (161 words)

The BD ProbeTec ET Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) Amplified DNA Assays, when tested with the BD ProbeTec ET System, use Strand Displacement Amplification (SDA) technology for the direct, qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA in endocervical swabs, male urethral swabs, and in female and male urine specimens as evidence of infection with C. trachomatis, N. gonorrhoeae, or of co-infection with both C. trachomatis and N gonorrhoeae. Specimens may be from symptomatic or asymptomatic females and males. A separate Amplification Control is an option for inhibition testing (BD ProbeTec ET CT/GC/AC Reagent Pack). The BD ProbeTec ET CT/GC assays may be performed using either the BD ProbeTec ET System or a combination of the BD ProbeTec ET System and BD Viper instrument.

The BD Viper System, when used with BD ProbeTec ET amplified nucleic acid assays, is intended for the in vitro detection of targeted organisms from specimens as identified in the assay-specific reagent package insert(s).

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K052481: BD Viper System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K052481

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026